tetano
Editor, Senior Moderator
Antiviral Res. 2017 Jun 17. pii: S0166-3542(17)30042-6. doi: 10.1016/j.antiviral.2017.06.012. [Epub ahead of print]
[h=1]A cross-clade H5N1 influenza A virus neutralizing monoclonal antibody binds to a novel epitope within the vestigial esterase domain of hemagglutinin.[/h] Paul SS[SUP]1[/SUP], Mok CK[SUP]1[/SUP], Mak TM[SUP]2[/SUP], Ng OW[SUP]1[/SUP], Aboagye JO[SUP]3[/SUP], Wohlbold TJ[SUP]4[/SUP], Krammer F[SUP]5[/SUP], Tan YJ[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The sporadic outbreaks of highly pathogenic H5N1 avian influenza virus have raised public health concerns. Monoclonal antibodies (MAbs) against hemagglutinin (HA) have been increasingly used successfully for therapeutic purposes. Previously, MAb 9F4, generated against clade 1 H5N1 HA, was observed to have cross-clade neutralizing efficacy and inhibited viral entry by preventing the pH-mediated conformational change of HA. Furthermore, mouse-human chimeric MAb 9F4 was found to retain high degrees of neutralizing activity. In this study, through escape mutant generation and in-silico prediction, it was revealed that MAb 9F4 binds to a novel epitope in the vestigial esterase sub-domain of HA comprising at least three non-continuous amino acid residues, arginine (R) at position 62, tryptophan (W) at position 69 and phenylalanine (F) at position 79, which interacted with MAb 9F4 in a conformation-dependent manner. Binding and neutralization studies suggested that R62 is the critical residue for MAb 9F4 binding whereas W69 and F79 seem to cooperate with R62 to stabilize the epitope. Mutation of either R62 or W69 did not affect replicative fitness of the virus in vitro. Interestingly, MAb 9F4 retained neutralizing efficacy against a clade 2.3.2.1a H5N1 virus consisting of an arginine to lysine substitution at position 62 in HA.
Copyright ? 2017. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] Epitope mapping; Hemagglutinin; Influenza H5N1; Neutralizing monoclonal antibody
PMID: 28633988 DOI: 10.1016/j.antiviral.2017.06.012
[h=1]A cross-clade H5N1 influenza A virus neutralizing monoclonal antibody binds to a novel epitope within the vestigial esterase domain of hemagglutinin.[/h] Paul SS[SUP]1[/SUP], Mok CK[SUP]1[/SUP], Mak TM[SUP]2[/SUP], Ng OW[SUP]1[/SUP], Aboagye JO[SUP]3[/SUP], Wohlbold TJ[SUP]4[/SUP], Krammer F[SUP]5[/SUP], Tan YJ[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The sporadic outbreaks of highly pathogenic H5N1 avian influenza virus have raised public health concerns. Monoclonal antibodies (MAbs) against hemagglutinin (HA) have been increasingly used successfully for therapeutic purposes. Previously, MAb 9F4, generated against clade 1 H5N1 HA, was observed to have cross-clade neutralizing efficacy and inhibited viral entry by preventing the pH-mediated conformational change of HA. Furthermore, mouse-human chimeric MAb 9F4 was found to retain high degrees of neutralizing activity. In this study, through escape mutant generation and in-silico prediction, it was revealed that MAb 9F4 binds to a novel epitope in the vestigial esterase sub-domain of HA comprising at least three non-continuous amino acid residues, arginine (R) at position 62, tryptophan (W) at position 69 and phenylalanine (F) at position 79, which interacted with MAb 9F4 in a conformation-dependent manner. Binding and neutralization studies suggested that R62 is the critical residue for MAb 9F4 binding whereas W69 and F79 seem to cooperate with R62 to stabilize the epitope. Mutation of either R62 or W69 did not affect replicative fitness of the virus in vitro. Interestingly, MAb 9F4 retained neutralizing efficacy against a clade 2.3.2.1a H5N1 virus consisting of an arginine to lysine substitution at position 62 in HA.
Copyright ? 2017. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] Epitope mapping; Hemagglutinin; Influenza H5N1; Neutralizing monoclonal antibody
PMID: 28633988 DOI: 10.1016/j.antiviral.2017.06.012